FINWIRES · TerminalLIVE
FINWIRES

Exelon Q1 Expands Capex Plan, Transmission Pipeline Grows

By

-- Exelon (EXC) posted Q1 utility earnings Wednesday, while expanding its capital investment plans for 2026-2029.

Exelon's capex plans include investments of about $41.7 billion over 2026-2029, with a growing share allocated to transmission, alongside an additional $12-17 billion in potential transmission upside.

The revised capital plan reflects a 7.9% target rate base growth annually.

Exelon outlined a data center-driven growth pipeline of about 18-19 GW of potential load, with about 45% already secured with Transmission Service Agreements as of the Q4 2025 call.

The company said it operates 11,197 transmission lines, including about 3,300 circuit miles of extra high-voltage line.

On project activity, Exelon said the PJM board approved about $1.7 billion in partnered projects under the 2025 Regional Transmission Expansion Plan Window 1 process.

The company also submitted two partnered bids in MISO's Long Range Transmission Planning Tranche 2.1, targeting roughly $1.9 billion in transmission projects in Illinois.

The US-regulated electric and gas utility operator said Q1 utility earnings strengthened overall, supported by approved distribution and transmission rate increases at subsidiaries, Commonwealth Edison and Pepco, as well as distribution rate approvals at Baltimore Gas and Electric.

Additional tailwinds included the absence of prior customer surcharge credits at PECO Energy, higher allowance for funds used during construction at ComEd, and favorable weather conditions and lower income taxes at PECO.

The company noted that recent rate increases reflect updated cost-recovery mechanisms tied to infrastructure investment, which it said support reliability and help reduce outage-related costs.

Price: $45.93, Change: $-0.25, Percent Change: -0.54%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL